Clinical Trials Logo

Monoclonal Gammopathy clinical trials

View clinical trials related to Monoclonal Gammopathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03236428 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Start date: November 24, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab